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Abstract With a growing interest of the involvement of
extracellular nucleotides in both normal physiology and
pathology, it has become evident that P2 receptor
agonists and antagonists may have therapeutic potential.
The P2Y2 receptor agonists (diquafosol tetrasodium and
denufosol tetrasodium) are in the phase 3 of clinical
trials for dry eye and cystic fibrosis, respectively. The
thienopyridine derivatives clopidogrel and ticlopidine
(antagonists of the platelet P2Y12 receptor) have been
used in cardiovascular medicine for nearly a decade.
Purines and pyrimidines may be of therapeutic potential
also in wound healing since ATP and UTP have been
shown to have many hallmarks of wound healing factors.
Recent studies have demonstrated that extracellular
nucleotides take part in all phases of wound repair:
hemostasis, inflammation, tissue formation, and tissue
remodeling. This review is focused on the potent purines
and pyrimidines which regulate many physiological
processes important for wound healing.
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EGF Epidermal growth factor
EGFR Epidermal growth factor receptor
ERK Extracellular-signal-regulated kinase
FGF Fibroblast growth factor
GPCR G protein-coupled receptor
HAECs Human aortal endothelial cells
HMVECs Human microvessel endothelial cells
HUVECs Human umbilical vein endothelial cells
IFN Interferon
IGF Insulin-like growth factor
IL Interleukin
LCs Langerhans cells
MAPK Mitogen associated protein kinase
MMP Metalloproteinase
NHK Normal human keratinocytes
PAI Plasminogen activator inhibitor
PDGF Platelet-derived growth factor
PI3K Phosphoinositol 3-kinase
THCE SV-40 immortalized human corneal epithelial
HCE cell line
TGF Transforming growth factor
TNF Tumor necrosis factor
VEGF Vascular endothelial growth factor
VEGFR Vascular endothelial growth factor receptor
VSMCs Vascular smooth muscle cells
VVEC Vasa vasorum endothelial cells
Introduction
Extracellular adenosine 5′-triphosphates and 5′-diphos-
phates (ATP, ADP) as well as uridine-5′-triphosphate
(UTP) and uridine-5′-diphosphate (UDP) have been recog-
nized as important signaling molecules involved in the
E. Gendaszewska-Darmach (*): M. Kucharska
Institute of Technical Biochemistry, Faculty of Biotechnology




Purinergic Signalling (2011) 7:193–206
DOI 10.1007/s11302-011-9233-zregulation of many cellular processes. Since P2 receptors
activated by nucleotides are expressed in nearly all cell types,
purines and pyrimidines have a key role in the regulation of a
variety of functions in many tissues. Abbracchio and Burn-
stock, on the basis of molecular structure and transduction
mechanisms, divided P2 purinoceptors into two major
families: a P2X family of ligand-gated ion channel receptors
and a P2Y family of G protein-coupled receptors [reviewed in
1]. The P2X family consists of seven subtypes (P2X1-7), and
these form channels made by the assembly of subunit of the
same (homo-oligomers) or different (hetero-oligomers) sub-
types. For example, heteromultimers are clearly established
for P2X2/3 receptors. P2X1/2, P2X1/5, P2X2/6, P2X4/6,
and more recently P2X1/4 heteromultimers have also been
identified. P2X7 does not form heteromultimers, and P2X6
does not form a functional homomultimer. The stoichiom-
etry of P2X(1–7) receptors is thought to involve three
subunits, which form a stretched trimer or a hexamer of
conjoined trimers. cDNA cloning of P2X receptors has
revealed that each subunit in this receptors has two
membrane-spanning domains (TM1 and TM2), the N-
termini and C-termini are within the cell and the bulk of
the receptor protein is extracellular [2]. The P2Y family
consists of eight receptors which are divided based on
coupling to specific G proteins, overall sequence similar-
ity and second messenger responses. P2Y receptors
consist of seven membrane spanning domains and eight
subtypes have been identified: P2Y1, P2Y2, P2Y4, P2Y6,
P2Y11, P2Y12, P2Y13, and P2Y14. Whereas P2X
receptors tend to be activated principally by adenine
nucleotides, P2Y receptors are activated by adenine and/
or uracil nucleotides. The P2Y1 receptor responds to
ADP > ATP but not to UTP while the P2Y2 receptor
responds to both ATP and UTP and the P2Y4 responds to
U T P>A T Pi nh u m a n s[ 3]. The P2Y6 subtype responds
preferentially to UDP and has little affinity for ATP and
the P2Y11 responds to ATP but not to UTP [4]. P2Y12 [5]
and P2Y13 [6] are activated by ADP. P2Y14 is activated
by UDP-glucose [7]. The P2Y receptors are unusual in
comparison to other cluster of GPCR sequences because they
respond to varied and diverse nucleotide ligands. P2Y
receptors couple to one or more heterotrimeric G proteins,
includingGq/11,G s,G i/o,a n dG 12/13 resulting in the activation
of various signaling pathways [reviewed in 1, 8, 9].
The majority of studies involving purinergic signaling
has been concerning their role in short-term events, such as
neurotransmission, secretion, or regulation of the vascular
hemostasis. However, there is growing interest in the long-
term trophic effects of extracellular nucleotides on cell
growth, proliferation, and death. Several studies over the
past decade have shown that nucleotides released from
damaged tissues also regulate many important functions of
skin cells, including proliferation, migration, and contraction.
Short- and long-term effects after injury are mediated by
nucleotides and can promote wound healing [10, 11]. This
review is focused on the potent purines and pyrimidines
which regulate many physiological processes important for
wound healing. The latest findings of application of
extracellular nucleotides have indicated that interventions in
purinergic signaling might also provide new therapeutic
approaches for the treatment of wound healing.
Sources of nucleotides in the wound
Nucleotides are released from cells by mechanical stimula-
tion, ligand binding, exocytotic release, or injury. The
concentration of extracellular nucleotides is low in healthy,
non-damaged tissues (e.g., ATP is approximately 10 nM)
despite the cytosolic concentration is very high (3–10 mM
in the case of ATP) [12]. Cell damage, acute cell death, or
environmental stimuli (mechanical stress, osmolarity
change, and oxidative stress) trigger the release of
nucleotides from cells. Cell injury initiates the release of
various growth factors in the wound bed as well as it causes
an outflow of nucleotides that reaches the range for P2
receptor activation. Epidermis is the skin layer which is
exposed to most stimuli activating the release of nucleo-
tides. It consists principally of keratinocytes which are
stratified, squamous, epithelial cells of a highly dynamic
structure. Dixon et al. have demonstrated that even under
static conditions, normal human keratinocytes release ATP
reaching concentration of approximately 17 nM [13]. Also,
cultures of an immortal HaCaT keratinocyte cell line
release ATP in a cell number-dependent manner [14]. It
has also been reported that normal human keratinocyte
cultures as well as human keratinocyte A431 cell line
release ATP in response to cell damage by irritant
chemicals reaching almost 30 μM concentration mainly
by disrupting membrane lipid bilayers [15]. Yin et al. have
observed ~15 nM ATP release from transfected human
corneal epithelial (THCE) resting cells (an SV-40 immor-
talized corneal epithelial HCE cell line) [11]. However,
such concentration of ATP are below the range to activate
purinoceptors. Scratch wounds of THCE cells have resulted
in ATP release from damaged cells into the culture medium
(1.25 μM). This suggests that in vivo at the moment of cell
injury the extracellular ATP concentration reaches the range
for P2 receptor activation. Yin et al. have also demonstrated
that extracellular ATP concentration is elevated after
wounding in bronchial and intestinal epithelial cells,
indicating that injury-caused ATP release might be a
common scenario among epithelial cells.
Tissue injury also causes the blood vessel disruption
with concomitant extravasation of blood constituents
followed by the release of nucleotides from platelets.
194 Purinergic Signalling (2011) 7:193–206During wounding, one of the first steps is activation of
platelets occurring by binding to collagen that becomes
exposed following rupture of the endothelial lining of
vessels (Fig. 1). Platelet activation is characterized by rapid
shape change, release of granular contents, generation of
lipid mediators, and aggregation [16]. Dense granules (also
called delta-granules or dense bodies) are packed with
serotonin, calcium, ATP, ADP, and pyrophosphate. Platelets
contain 40 nmol of ATP and ADP per mg of protein.
Because concentration of ATP within the storage granules
is very high (~100 mM) its plasma concentration at sites of
massive platelet aggregation reaches 20–50 μM[ 17, 18].
ATP and ADP released upon platelet activation act in a
positive feedback manner (i.e., activating other resting
platelets) thus amplifying the initial response.
Among constituents of blood neutrophils are primary
phagocytic cells with important roles in tissue repair. A key
feature of neutrophils is their ability to detect and migrate to
compromised tissues following a concentration gradient of
chemotactic substances released from injured cells. Neu-
trophils can detect a 1% difference in the concentration of
chemoattractant [19]. Human neutrophils release ATP from
the leading edge of the cell surface to amplify chemotactic
signals what helps neutrophils locate damaged tissues,
which also generate extracellular ATP [20]. Besides
platelets and leukocytes erythrocytes are an additional
important source of extracellular ATP in the wound. ATP
is released from erythrocytes upon exposure to low oxygen
tension and mechanical deformation. Sprague et al. reported
that both rabbit and human erythrocytes release ATP in
response to mechanical deformation [21]. Mechanical
deformation can occur as the erythrocyte passes through
small resistance vessels and capillaries of the microcircu-
lation or in response to increases in linear flow velocity.
Human erythrocytes have also been reported to release ATP
in response to decreased oxygen tension [22].
The concentration of extracellular nucleotides is elevated
at the site of vascular injury because nucleotides are
released not only from activated platelets, neutrophils, or
erythrocytes but also from endothelial cells, vascular
smooth muscle cells, and fibroblasts which are the main
cellular component of the blood vessel wall. It has been
shown that even nonlytic stimuli such as increased flow rate
cause the increased release of pharmacologically relevant
amounts of ATP from endothelial cells [23] and fibroblasts
[24]. Bodin et al. have shown that vascular smooth muscle
cells (VSMCs) freshly isolated from the rabbit thoracic
aorta are unable to release ATP when subjected to increased
flow [25]. However, recent data have indicated shown that
mechanical stimulation (washes with PBS) triggers rapid
release of endogenous ATP and other low molecular mass
metabolites into the extracellular compartment in the case
of rat vascular smooth muscle cells [26]. Endothelial cells
in the vascular system are continuously exposed to
mechanical forces due to the pulsatile nature of blood flow
and shear stress. During injury, increased shear stress can
additionally cause endothelial cell perturbations and the
release of a large amount of nucleotides. Since VSMCs and
fibroblasts lay underneath the endothelial layer, they are not
directly exposed to mechanical shear stress associated with
blood flow. However, after the endothelium is disrupted by
injury, the latter cells may also be directly exposed to
arterial shear stress and they may be modulated by changes
in the local hemodynamic environment. Thus these hemo-
dynamic forces play an important role in the regulation of
wound healing since mechanical stimuli associated with
blood flow play an important role in the regulation of
vascular remodeling.
Hypoxia which is associated with tissue damage also
contributes to the elevated levels of nucleotide release at the
site of injury. Many cell types, including endothelial cells
[27], fibroblasts [28], and erythrocytes [22, 29] release ATP
in response to hypoxia.
Much less is known about sources and release mecha-
nisms of UTP. However, UTP has been detected in low
nanomolar concentrations in the extracellular medium of
many cells examined under resting conditions, and en-
hanced UTP levels has been observed after mechanical
stimulation. The concentration of UTP measured in the
medium bathing ~3×10
5 tissue culture cells under basal
conditions ranges from 1 to 5 nM. The ratio of 1:3–5 for






Fig. 1 Cellular events during different stages of wound healing
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able tissues both in resting and mechanically stimulated
conditions, closely reflecting the relative intracellular
abundance of these nucleotides. Thus, a common source
and perhaps a common mechanism of release may exist for
both ATP and UTP [30, 31].
Expression of nucleotide receptors on cells involved
in wound healing
Release of high local concentrations of ATP and UTP
activates P2 receptors found at the surface of the skin cells
involved in wound healing (Table 1). Since injury causes
the release of intracellular nucleotides, the released ATP
and UTP can act as a “cell-damage” signal to trigger cell
signaling events including Ca
2+ waves and G-protein-
coupled receptor activation. Reepithelialization is a critical
step in wound healing. During this process, keratinocytes,
the predominant epidermal cells, exhibit increased prolifer-
ation and enhanced migration. P2 receptors are expressed in
spatially distinct zones of the epidermis where they may
regulate different cellular functions (e.g., P2X5 and P2X7
are preferentially expressed in the stratum spinosum and
stratum corneum, respectively, where they promote differ-
entiation) [32]. In situ hybridization has revealed a
localization of P2Y2 receptor transcripts in the basal cell
layer of skin sections [13]. In vitro, the expression of
mRNA for P2Y1, P2Y2, P2Y4, and P2Y6 receptors has
been demonstrated in HaCaT cells and differentiated and
undifferentiated normal human keratinocytes (NHK). How-
ever, in NHK, only the P2Y2 receptor subtype seems to be
functional and evidence for functional P2Y1, P2Y2, and
P2Y4 receptors in HaCaT has been confirmed [14].
Yoshida et al. demonstrated that HaCaT cells express
P2X5 and P2X6 receptor mRNAs as P2X receptor subtypes
[33]. P2X7 receptor mRNA was also detected to a small
extent. They also showed expression of mRNAs for P2Y1,
P2Y2, P2Y6, P2Y11, and P2Y12 receptors. Slight expres-
sion of P2Y4 receptor was also detected. The expression
patterns of multiple P2Y and P2X receptor in normal
human keratinocytes were also analyzed by Inoue et al.
[34]. They confirmed the expression of P2X1, P2X4, P2X5,
P2X6, P2X7, P2Y1, P2Y2, P2Y4, P2Y11, P2Y12, and
P2Y13 receptors. Although the expression levels of P2
receptors varied in all samples, P2Y1, P2Y11, and P2X5
receptor subtypes were consistently expressed. The expres-
sion of P2Y2 was detected in three of four strains. The
expression of P2Y12 was detected in one of four strains.
P2Y13 was detected in two of four strains. The expression
of P2X1 and P2X4 was detected in three of four strains.
The expression of P2X7 was detected in two of four strains
and the expression of P2X6 was detected in one strain.
Apart from keratinocytes which are the largest popula-
tion of epidermal cells in the skin (up to 95%), melano-
cytes, Langerhans’ cells and Markel cells are present within
the epidermis. Langerhans cells (LCs) are an important
subclass of dendritic cells that reside in the epidermis.
Monocyte-derived dendritic cells have been shown to
express P2X1, P2X4, P2X7, P2Y1, P2Y2, P2Y5, and
P2Y11 receptors [35]. LC-like cell line has been found to
express mRNA for P2X1, P2X7, P2Y1, P2Y2, P2Y4,
P2Y9, and P2Y11 receptors [36]. Georgiou et al. have
demonstrated that functional P2X7 is present on human
epidermal LCs and monocyte-derived LCs [37].
While P2Y1, P2Y2, P2Y6, and P2X7 have been
described in the human melanoma cell lines and tissues
[38, 39], relatively little is known about the expression in
melanocytes. Deli et al. have observed some faint nuclear
P2X7 immunopositivity in primary human melanocyte
cultures melanocytes; however, they have shown no
response to ATP [40].
Fibroblasts are considered to be the major cell type of
the dermis and they participate in a complex process of
tissue repair. Cutaneous tissue damage induces a proin-
flammatory reaction resulting in the activation of fibroblasts
which repopulate the damaged area during the granulation
phase of tissue repair. Tissue fibroblasts represent the main
source of cells for promoting the reconstruction of the
connective tissue in the wound. In human dermal fibro-
blasts, reverse transcription polymerase chain reaction
(RT-PCR) amplification has revealed expression of P2X3,
P2X4, P2X7, P2Y1, P2Y2, P2Y4, and P2Y6 receptors [41].
Solini et al. have also provided evidence for existence
functional P2X7 receptor in these cells [42]. Among P2
receptor subclasses expressed in human fibroblasts isolated
from skin biopsies, P2Y6 and P2X7 mRNA are not
detected in subepithelial fibroblasts of rat small intestinal
villi. In the latter cells, P2Y1 and P2Y4 mRNA are
dominantly expressed and P2Y2 and P2X1 have minor
intensity [43].
During normal wound healing, fibroblasts migrate to the
wound area and differentiate into myofibroblasts under the
influence of growth factors such as transforming growth
factor β1 (TGF-β1) and the mechanical stress developed
within a given tissue [reviewed in 44]. Myofibroblasts are
an unique group of cells phenotypically intermediate
between smooth muscle cells and fibroblasts. They are
characterized by the presence of stress fibers containing the
α-actin isoform that is expressed in smooth muscle cells
and they disappear with the completion of healing. Little
information is available about expression of nucleotide
receptors on human dermal myofibroblats. Rat cardiac
myofibroblasts express six P2Y receptor subtypes (P2Y1,
2, 4, 6, 11, 13), however only five (P2Y1, 2, 4, 6, 11) have
been functionally detected [45]. Guinea pig suburothelial
196 Purinergic Signalling (2011) 7:193–206myofibroblasts are strongly labeled with the P2Y6 anti-
body. There is weaker staining for P2X3, P2Y2, and P2Y4,
but none to P2Y1 [46]. Expression of P2X3 purinoceptors
in suburothelial myofibroblasts of the normal human
urinary bladder has been confirmed by Liu et al. [47].
Liang et al. have reported that P2Y2 receptor stimulation by
ATP and UTP induces endoplasmic reticulum Ca
2+ release
and Ca
2+ influx in human valvular myofibroblasts [48].
Since myofibroblasts are ubiquitous cells with similar
properties and functions that have similar morphological
characteristics and function regardless of their tissue
location, one may presume that at least P2X3 and P2Y2
receptors are present on human dermal myofibroblats.
Mast cells also play a fundamental role in remodeling
and repair process by protecting against bacterial infection
and maintain tissue homeostasis. Human mast cells from
different sources express different pattern of nucleotide
receptors due to their heterogeneity. For example, mast cells
isolated from lung and skin do not express P2X7 while this
receptor is highly expressed by HMC-1 cell line and
activated human cord blood mast cells (CBMCs). Mast
cells isolated from human skin express P2X1 and show
only a marginal P2X4 receptor expression [49]. CBMCs
express mRNA for P2X1 and P2X4 as well as for P2Y1,
P2Y2, P2Y11, P2Y12, and P2Y13 [50]. Expression pattern
of P2Y receptor subfamily in mast cells isolated from
human skin has not been analyzed yet.
Endothelial cells, vascular smooth muscle cells, and
fibroblasts are a key structural element of the blood vessel
walls. Blood vessel regeneration is a vital component of
normal wound healing. This process occurs through both
angiogenesis (sprouting of capillaries from existing blood
vessels) and vasculogenesis (mobilization of bone marrow-
derived endothelial stem cells). The most commonly used
human endothelial cell for in vitro angiogenesis assays are
human umbilical vein endothelial cells (HUVEC). Func-
tional expression of P2X4 receptors, but not of P2X1,
P2X2, P2X3, and P2X5 receptors on HUVEC plasma
membranes has been reported [51]. Northern blot analysis
used in that study has demonstrated that P2X4 mRNA is
expressed in HUVECs, human aortal endothelial cells
(HAECs), human pulmonary artery endothelial cells
(ECs), and human microvessel ECs. P2X1 is not expressed
in any of EC lines studied. P2X4 is the most strongly
expressed isoform in the HAECs and the P2X7 mRNA
levels are 30% of the P2X4 mRNA level. P2X3 and P2X5
expressions are 3% of the P2X4 level. Similar P2X subtype
mRNA expressions has been seen in HUVECs as well.
These findings suggest that endothelial cells predominantly
express P2X4 receptors among P2X receptor studied. Using
confocal and electron microscopy, Glass et al. have
demonstrated that P2X4 and P2X6 receptors show a similar
expression pattern and they are closely colocalized with
VE-cadherin [52]. Using real-time PCR and Western
blotting analysis, it has been also demonstrated that the
P2X4, P2Y11, P2Y1, and P2Y2 are the most expressed P2
receptors in HUVECs [53]. With regard to the fact that
angiogenesis commonly involves the microvasculature
rather than the macrovasculature, it should be taken into
account differences between the lineage of these. Seiffert et
al. have found strong expression of the P2X4, P2X5, P2X7,
P2Y2, and P2Y11 receptors in transformed human micro-
vascular endothelial cells, whereas expression of P2X1 and
P2X3 has been faint [54].
Wang et al. have shown that P2X1, P2Y2, and P2Y6
receptors are the most expressed in human smooth muscle
cells obtained from mammary artery [53]. RT-PCR analysis
of endothelium-denuded human cerebral and omental
arteries has demonstrated P2X1, P2Y1, P2Y2, and P2Y6
receptor mRNA expression. There has been no bands for
the P2Y4 receptor mRNA in the omental arteries, while
barely detectable in the cerebral arteries [55]. RT-PCR
analysis of mRNA from endothelium-denuded human
coronary arteries has demonstrated strong bands for P2Y2
and P2X1, although bands for P2Y1, P2Y4, and P2Y6
receptor mRNA could also be detected [56]. Similar results
have been reported from rat arterial smooth muscle cells
showing the P2Y2 receptor mRNA to be 10- and 100-fold
more highly expressed than P2Y6 and P2Y4, respectively.
The expression of the P2Y1 receptor was lower than that of
the P2Y4 receptor [57].
All cell types involved in wound healing differentially
express P2X and P2Y receptors, and the receptor expression
patterns vary between cellular types. Moreover, differential
expression of nucleotide receptor subtypes contributes to
tissue cell heterogeneity which might be responsible for
inducing a variety of responses by nucleotides present in the
site of wounding.
Extracellular nucleotides in hemostasis
and inflammation
Wound healing is a highly dynamic process involving
interactions of extracellular matrix molecules, soluble
mediators, and various cells that cooperate to repair formed
injury. Wound repair is divided into four phases that
overlap in time and space: hemostasis, inflammation, tissue
formation (proliferative phase), and tissue remodeling
(Fig. 1). All these phases exert specific contributions on
blood vessel growth and remodeling [58].
Hemostasis and inflammation are first phases of tissue
repair. Hemostasis is caused by leak of blood constituents
and vasocative factors into the wound site. Platelets start to
aggregate at the damaged site to form a fibrin clot which
control active bleeding and facilitate invasion and migration
Purinergic Signalling (2011) 7:193–206 197of endothelial cells. Inflammatory phase is characterized by
influx of polymorphonuclear leukocytes (neutrophils).
Bacteria and debris are phagocytosed and then removed
from the injury. In addition, inflammatory cells release
angiogenic growth factors and proinflammatory cytokines,
which control the recruitment of inflammatory and endo-
thelial cells into the wound site. Immediately after injury,
coagulation and hemostasis take place in the wound since
platelet and coagulation factor-dependent thrombus forma-
tion is critical to limit posttraumatic blood loss at sites of
vascular injury.
During the hemostasis phase of skin wound healing,
extracellular nucleotides are abundant and play a crucial
role in triggering thrombus formation. At the site of injury,
activated platelets release ADP from their dense granules,
which functions as a positive feedback mediator that binds
to the receptors on the platelets’ surface. Stimulation of the
P2Y1 receptor mobilizes intracellular calcium and triggers a
change in the platelet shape, aggregation, thromboxane A2
generation, procoagulant activity, adhesion to immobilized
fibrinogen, and thrombus formation. ADP also activates
P2Y12 receptor resulting in lowering of cyclic adenosine
monophosphate level, amplification of the platelet re-
sponse, stabilization of the resulting aggregates, and
secretion of further mediators from the granules. The third
P2X1 receptor present on platelets is an ATP-gated ion
channel that upon activation causes an influx of calcium.
The role of platelet P2X1 signaling is less well defined with
respect to platelet activation and thrombus formation but it
is known to cause shape change and support the activation
process of other agonists [reviewed in 59].
Activated platelets trapped into the clot also release
growth factors and proinflammatory cytokines which
control the recruitment of inflammatory cells, endothelial
cells, and fibroblasts into the wound site. ATP, ADP, and
other nucleotides also act as a “danger-associated” molec-
ular signal and affect various immunocompetent cells such
as neutrophils, mast cells, dendritic cells, and dermal
endothelial cells. Neutrophil recruitment to the site of
inflammation is triggered by extracellular nucleotides.
Verghese et al. have shown that ATP and UTP induce actin
polymerisation and chemotaxis in human neutrophils via
the activation of P2Y2 receptor [60]. Besides P2Y2, human
neutrophils express P2X7, P2Y4, P2Y6, and P2Y11
receptor subtypes [61–63]. It has been found that human
neutrophils release ATP from the leading edge of the cell
surface to amplify chemotactic signals what helps neutro-
phils locate damaged tissues, which also generate extracel-
lular ATP [20]. Chen et al. have recently shown that ATP is
released from neutrophils through pannexin-1 hemichan-
nels and P2Y2 purinergic signaling is a fundamental
mechanism required for neutrophil activation and immune
defense [64].
ATP has also chemotactic properties towards eosinophils
and together with UDP induces secretion of interleukin
(IL)-8 by eosinophils. Activation of nucleotide receptors
expressed on human macrophages induces secretion of
IL-1β, tumor necrosis factor (TNF)-α, or IL-18 [reviewed in
65]. Warny et al. demonstrated that UDP activates IL-8 gene
expression and IL-8 release in human monocytic cells [66].
ATP and UTP, probably via activation of the P2Y2, as well
as ADP (via P2Y1) are thought to be potent chemotactic
stimuli also for immature but not for mature DCs [67].
Besides direct chemotactic effects on DCs, extracellular
nucleotides are also involved indirectly via their action on
DCs in the trafficking of other leukocytes through the release
of chemokines [reviewed in 65]. Also, immunity of mast
cells is associated with extracellular nucleotides, e.g., the
chemotaxis and degranulation are mediated by P2X7
induced calcium release [reviewed in 68].
All immune and inflammatory cells express P2Y and
P2X receptors (Table 2), and their expression is modulated
by inflammatory cytokines during development [69–73].
Among the P2 receptors, P2Y2, P2Y6, P2Y11, P2Y12,
P2X4, and P2X7 are closely associated with immune
responses. Special attention should be paid to the P2X7
subtype, as it is closely related to IL-1β and IL-18. IL-1β is
a potent proinflammatory agent that can be driven by P2X7
activation rather than by a passive process, as previously
thought. It is possible that P2X7 activation simultaneously
opens the potassium channel and facilitates IL-1β secretion.
Mice deficient in P2X7 exhibited markedly reduced
inflammation, pain, and IL-1β-mediated IL-6 production
[reviewed in 74].
Density of purinergic receptors may change during the
course of inflammatory responses [reviewed in 75]. For
example, the best characterized P2X7 receptors on in
monocytes and macrophages that are downregulated by
anti-inflammatory cytokines (e.g., IL-4, IL-10) whereas
they are upregulated by the proinflammatory mediators
(e.g., TNFα,I F N γ, and lipopolysaccharide). With the
upregulation of the P2X7 receptors, inflammatory activa-
tion of monocytes induces downregulation of the P2Y2
receptor [76, 77].
Extracellular nucleotides in tissue formation
Inflammatory mediators, released by macrophages and
neutrophils, serve as chemotactic agents for invading
fibroblasts and keratinocytes. The proliferative phase of
wound healing is characterized by fibroblast migration,
epithelialization, and wound contraction and deposition of
newly synthesized extracellular matrix, acting as a replace-
ment for the provisional network composed of fibrin and
fibronectin.
198 Purinergic Signalling (2011) 7:193–206Following injury, fibroblasts and myofibroblasts in the
surrounding tissue are activated to proliferate and migrate
into the wound. In the wound, they proliferate profusely
and produce the extracellular matrix proteins. Both,
fibroblasts and myofibroblasts play a crucial role in wound
healing by generating traction and contractile forces—to
enhance wound contraction. Myofibroblasts become the
most abundant in the proliferation phase of wound healing
and progressively disappear in the later stage of healing.
Fibroblasts are well-known not only for being the major
producers of extracellular matrix, but also a cell type
actively involved in synthesis of inflammatory mediators
Table 1 Expression of P2 receptor subtypes on cells involved in wound healing
Cell type Receptor subtypes Method of detection References
Keratinocytes
NHK P2Y1, P2Y2, P2Y4, P2Y6
P2X1, P2X4, P2X5, P2X6, P2X7, P2Y1,
P2Y2, P2Y4, P2Y11, P2Y12, and P2Y13
RT-PCR [12]
RT-PCR [34]
HaCaT P2X5, P2X6, P2Y1, P2Y2, P2Y6, P2Y11,
P2Y12 >> P2X7, P2Y4
RT-PCR [33]
Dermal fibroblasts P2X4, P2X7 > P2X3 RT-PCR [41]
P2Y1, P2Y2, P2Y4, P2Y6
Skin MC P2X1 >> P2X4 GeneChip [49]
Endothelium
HUVEC P2X4 > P2Y11 > P2Y1 > P2Y2 >>
P2Y4, P2Y6
RT-qPCR and Wb [53]
P2X4 >> P2X7 > P2Y1 > P2Y2 Competitive PCR analysis [51]
P2X4 = P2X6 Confocal and electron microscopy [52]
HAECs P2X4 >> P2X7 > P2Y1 > P2Y2 Competitive PCR analysis [51]
HPAEC P2X4 Nb [51]
HMVEC P2X4 Nb [51]
HMEC-1 P2X4, P2X5, P2X7, P2Y2, P2Y11 > P2X1 RT-PCR [54]
VSMCs P2X1 > P2Y2, P2X4 > P2Y6 > P2Y1, P2Y4 RT-qPCR and Wb [51]
Endothelium-denuded cerebral arteries P2X1 > P2Y2 > P2Y6 > P2Y1 >> P2Y4 RT-PCR [55]
Endothelium-denuded omental arteries P2X1 > P2Y1, P2Y2, P2Y6 RT-PCR [55]
Wb Western blot, Nb Northern blot, MC mast cells, qPCR quantitative PCR, RT-PCR reverse transcription PCR, HPAECs human pulmonary artery
ECs, HMVEC human microvessel endothelial cell, HMEC-1 transformed human microvascular endothelial cell line one
Table 2 Immune cell distribution of nucleotide receptor subtypes
Subtype Immune cell distribution References
P2X1 Neutrophils, eosinophils, lymphocytes, lymphocytes, monocytes, dendritic cells [65, 67, 70–72]
P2X2 Lymphocytes [65, 71]
P2X3
P2X4 Eosinophils, lymphocytes, monocytes, dendritic cells [65, 67, 69, 72]
P2X5 Dendritic cells [65, 72]
P2X6
P2X7 Eosinophils, B lymphocytes, T lymphocytes, monocytes, macrophages, dendritic cells [63, 67, 69–72]
P2Y1 Neutrophils, eosinophils, lymphocytes, monocytes, dendritic cells [65, 69, 70, 72]
P2Y2 Neutrophils, eosinophils, polymorphonuclear neutrophils, lymphocytes, monocytes, macrophages, dendritic cells [65, 67, 69, 70, 72]
P2Y4 Neutrophils, eosinophils, lymphocytes, monocytes, macrophages, dendritic cells [65, 67, 69, 70, 72]
P2Y6 Neutrophils, eosinophils, lymphocytes, monocytes, macrophages, dendritic cells [65, 69, 70, 72]
P2Y11 Neutrophils, eosinophils, lymphocytes, monocytes, dendritic cells [65, 67, 69, 70, 72]
P2Y12 Monocytes, lymphocytes, dendritic cells [65, 69]
P2Y13 Monocytes, lymphocytes, [65, 69]
P2Y14 Eosinophils, dendritic cells [65, 73]
Purinergic Signalling (2011) 7:193–206 199and tissue repair. Primary fibroblasts react to stimulation
with ATP with striking morphological alterations and an
increased formation of cytoplasmic microvesicles. In
addition, fibroblast P2X7 receptor triggers IL-6 release
[42]. IL-6 is one of the most important proinflammatory
cytokines, secreted from mononuclear phagocytes and
antigen-presenting cells as well as fibroblasts. Janssen et
al. have demonstrated that ATP acting on human pulmonary
fibroblasts via P2Y receptors (likely P2Y4, P2Y6, and/or
P2Y11 subtypes) induces increased gene expression of
P2Y4 receptors and TGF-β (an important modulator of
wound repair) [78]. Others have shown ATP to induce a
mitogenic response in human fibroblasts [79].
In parallel to the formation of granulation tissue, increased
proliferation and migration of keratinocytes takes place.
During reepithelialization, basal keratinocytes undergo mor-
phological changes required for their migration from the
wound margin over the denuded area [80]. Greig et al. have
reported that adult human epidermis express P2X5, P2X7,
P2Y1, and P2Y2 receptors, each of which is expressed in a
spatially distinct zone of the epidermis and has distinct
cellular functions [32]. P2Y1 and P2Y2 receptors are
involved in basal keratinocyte proliferation. P2X5 receptors
are found in proliferating and differentiating keratinocytes in
epidermis but they are likely to be more involved in
keratinocyte differentiation. As P2X7 receptors are strongly
linked to apoptosis P2X7 receptors are likely to be part of the
machinery of end-stage terminal differentiation/apoptosis of
keratinocytes in the stratum corneum. Thus, the turnover of
keratinocytes in the squamous epithelium of the epidermis is
strictly connected with differential distribution of nucleotide
receptors. Also, purinergic receptor expression is modulated
in regenerating epidermis, which suggests that these recep-
tors may have important functions during wound healing.
Reepithelization is the resurfacing of a wound with new
epithelium and consists of both migration and proliferation
of keratinocytes at the periphery of the wound. After injury,
keratinocytes become activated and change to a migratory
phenotype. As epidermal migration moves on, keratinocytes
at the wound margin begin to proliferate behind the actively
migrating cells. The resulting dense hyperproliferative
epithelium feeds the migrating sheets at the wound margins
[81]. Greig et al. have shown that P2X5, P2X7, P2Y1, and
P2Y2 receptor expression in the epidermis is altered during
wound healing. P2Y1 receptor expression is significantly
increased in keratinocytes of the regenerating epidermis of
the denervated wounds but P2Y2 receptor expression is
significantly decreased. The expression of P2X5 receptors in
keratinocytes is significantly increased during wound heal-
ings in suprabasal as well as basal keratinocytes. This could
represent part of the change of phenotype that keratinocytes
undergo in order to become migratory during the wound
healing process [82].
In vitro studies have revealed that in primary normal human
keratinocytes and in the HaCaT keratinocyte cell line P2Y2
receptor is the predominant functional receptor that mediates
several biological responses induced by ATP and UTP, such as
cell proliferation and IL-6 production [14, 33]. Taboubi et al.
have demonstrated that activation of P2Y2 by ATP and UTP
is also connected with inhibition of keratinocyte spreading
and lamellipodium dynamics, and disorganization of the actin
cytoskeleton and focal contacts [83]. Recent data has indicated
that in keratinocytes, P2Y2 signaling inhibits insulin-like
growth factor-I (IGF-I)-induced p110α- phosphoinositol
3-kinase (PI3K) activity in a G(q/11)-dependent manner
[84]. IGF-I activation of PI3K is an essential pathway for
migration that is required for epidermis wound healing. It has
been also shown that extracellular UTP delays IGF-I-induced
PI3K-mediated keratinocyte migration by inhibiting both cell
spreading and cell velocity. During skin wound healing,
extracellular nucleotides may have a dual function, i.e.,
inhibiting keratinocyte motility and facilitating migration of
other cell types (e.g., endothelial cells) [83, 85]o rv a s c u l a r
smooth muscle cells [86]. Besides antimotogenic properties,
purines and pyrimidines are involved in the proliferation of
keratinocytes acting synergistically with growth factors shown
to stimulate the process of wound healing (e.g., PDGF, TGF
alpha, and EGF) [87]. Resulting nucleotide-enhanced prolif-
eration of cells in the basal layer may promote healing of an
epidermal wound by replacing damaged epidermis.
The proliferative phase of wound healing is also charac-
terized by fibroblast migration and deposition of newly
synthesized extracellular matrix. Once in the wound, they
proliferate and produce the matrix proteins: hyaluronan,
fibronectin, proteoglycans, and type 1 and 3 procollagen.
Collagens are an important component in all phases of wound
healing. Synthesized by fibroblasts, they impart integrity and
strength to all tissues and play a key role, especially in the
proliferative and remodeling phases of repair. Janssen et al.
have reported that in cultured human pulmonary fibroblasts,
ATP increases gene expression two matrix proteins (collagen
A1 and fibronectin) approximately four to five times above
baseline [78]. Stimulation of ECM gene expression by
extracellular nucleotides has been also confirmed in other
cell systems. Recently, Waldman et al. have demonstrated
that supplementation with ATP has a profound effect on the
growth and maturation of the developed tissue [88].
Exogenous ATP has increased biosynthesis of collagen and
proteoglycans in isolated bovine articular chondrocytes.
Extracellular nucleotides in formation
of new blood vessels
Angiogenesis, the growth of new blood vessels is critical in
wound healing and takes place during all phases of the
200 Purinergic Signalling (2011) 7:193–206reparativeprocess.Sinceangiogenesisisa multistepprocess,it
has to be under a complex control system with proangiogenic
and antiangiogenic factors. One of the most important
proangiogenic factors is vascular endothelial growth factor
(VEGF). Extracellular purine and pyrimidine nucleotides also
have been shown to have many hallmarks of proangiogenic
factors. Stimulation of endothelial and smooth muscle prolif-
eration and migration by nucleotides is an important compo-
nent of establishment of new blood vessels. Endothelial cells
derived from large and small vessels express several types of
purinergic receptors (Table 1). ATP-, ADP-, UTP-, and UDP-
induced stimulation of P2Y receptors results in a mitogenic
effect on rat brain capillary endothelial cells [89], bovine
corneal endothelial cells [90], and guinea pig cardiac
endothelial cells [91]. UTP is angiogenic in the chorioallan-
toic membrane of the chicken embryos [91]. Also non-
hydrolysable nucleotide analogs commonly used in pharma-
cological studies (e.g., ATPγS, ADPβS) have strong prolif-
erative effect on HUVEC cells [92] .T h em i t o g e n i ce f f e c t so f
extracellular nucleotides have been demonstrated in rat,
porcine, bovine VSMC, and cells from human coronary
arteries, aorta, and subcutaneous arteries and veins [93].
Stimulation of porcine coronary smooth muscle cells with
UTP and ATP induces increase in cellular DNA content,
protein synthesis, cell number, and proliferating cell nuclear
antigen expression, indicating a mitogenic role for P2Y2
receptors [94]. It also has been shown that stimulation of the
P2Y2 receptor by ATP or UTP in smooth muscle cells and
human umbilical vein ECs leads to cell migration [57, 85].
Characterization of the signaling pathways contributing to
angiogenesis stimulated by extracellular nucleotides is impor-
tant in developing pharmacologic strategies for both pro- and
anti-angiogenic therapy. It has been reported that ERK1/2 and
PI3K pathways play a critical role in extracellular ATP-
induced proliferation of vascular smooth muscle cells [95]. In
human coronary artery endothelial cells, activated P2Y2
receptors can transactivate vascular endothelial growth factor
receptor-2 (VEGFR-2), suggesting a direct link between
extracellular nucleotides and angiogenesis signaling [96].
Rumjahn et al. have demonstrated that P2Y1 stimulation of
human endothelial cells activates VEGFR-2 intracellular
signaling to stimulate endothelial cell tubulogenesis, a direct
in vitro measure of angiogenesis [97]. In VSMCs extracel-
lular nucleotides also promote actin cytoskeletal reorganiza-
tion in a P2Y2 and Rho kinase-dependent manner [86].
Recently, it has been demonstrated that P2X7 activation
promotes the robust release of vascular endothelial growth
factor from primary human monocytes [98]. This new action
of P2X7 receptor suggests that it may not only participate in
inflammation and cell death but that it is also likely to be
important in the control of angiogenesis and wound repair.
Another link between purinergic signaling and angio-
genesis signaling concerns integrins. P2Y2 receptor con-
tains the consensus integrin-binding domain arginine-
glycine-aspartic acid in its first extracellular loop that binds
selectively to αvβ3/β5 integrins [99]. P2Y2 colocalization
with αvβ3 integrin enables nucleotides to activate integrin-
associated responses such as cytoskeletal rearrangements
that control cell migration. In human endothelial cells, ATP
and UTP stimulates phosphorylation of several proteins that
are associated with integrin signaling and involved in focal
adhesion: focal adhesion kinase (FAK), paxillin, and p130
Crk-associated substrate (p130
cas), leading to EC spreading
and migration [85].
Angiogenesis occurring during various pathological con-
ditions (e.g., tissue damage) is connected with hypoxic
conditions. Hypoxia has been shown to stimulate release of
ATP from both cells of the vascular wall as well as circulating
blood cells. Studies on human HUVEC and bovine aortic EC
have demonstrated that hypotonic stress-induced ATP release
is mediated by a mechanism that involves actin cytoskeleton
reorganizationandactivationofRho/ROCKandFAK/paxillin
pathways [100, 101]. Hypoxia also results in time- and
O2-dependent ATP release from pulmonary artery adventitial
vasa vasorum endothelial cells (VVEC) [102]. It has been
shown that extracellular ATP and ADP exert angiogenic
effects on isolated VVECs characterized by expansion under
hypoxic conditions [103]. In VVECs, ATP augments the
effects of other angiogenic factors (VEGF and basic FGF)
known to be present in the hypoxic microenvironment and
PI3K/Akt/mTOR and ERK1/2 play a critical role in
mediating the extracellular ATP-induced mitogenic and
migratory responses. It has been also demonstrated that
P2Y1 and P2Y13 receptors play a major role in VVEC
growth responses [104].
It should be taken into consideration that once released,
ATP is rapidly hydrolyzed to ADP, AMP, and finally,
adenosine. A product of extracellular ATP hydrolysis,
adenosine, has been also shown to be angiogenic for both
microvascular and macrovascular endothelial cells
[reviewed in 105]. However, Gerasimovskaya et al. have
demonstrated that hypoxia not only induces release of ATP
into the extracellular milieu from fibroblasts and endothelial
cells but also delayed ATP hydrolysis [28]. Acute hypoxia
induces significant increases in extracellular ATP, support-
ing the possibility of autocrine-induced changes in purino-
ceptor activation and subsequent cell signaling.
Extracellular nucleotides in remodeling
Metalloproteinases and their inhibitors are involved in the
control of all aspects of wound healing. Metalloproteinase
cleavage of signaling molecules and ECM proteins occurs
during the inflammatory phase, where MMPs, especially
MMP-1, -3, -7, and -9, are capable of regulating chemokine
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play a role in rapid release of MMP-9 from monocytes,
which is required in the early phase of the inflammatory
response [106]. Degradation of cell adhesion molecules as
well as ECM proteins by MMPs is also necessary during
the repair phase, where MMP-1, 7-, -9, and -10 are required
for cell migration. Finally, during the remodeling phase of
wound healing, MMP-1, -3 and -13 as well as MMP-14 are
capable of cleaving collagen, and MMP-7 can process
elastin [107]. The remodeling of the newly formed
granulation tissue is responsible for the development of
new epithelium and final scar tissue formation. Waldman et
al. have recently demonstrated that ATP stimulates expres-
sion of MMP-13 (also known as collagenase-3) in cultures
of isolated bovine articular chondrocytes [88]. ATP has
been also shown to promote expression of MMP-3 and
MMP-13 in prostate cancer cells [108].
The remodeling process is dependent not only on the
coordinated activity of members of the matrix metal-
loproteinase family but also on components of the
plasminogen activation system, which converts the inactive
plasminogen to the serine protease plasmin. Plasmin
cleaves fibrin, dissolves the fibrin-containing clot which
may cause occlusion of the vessel or block cell migration
during tissue healing. Plasmin also digests ECM proteins,
including laminin and fibronectin as well it activates several
MMPs, including MMP-1, -13, -9, -3, -7 [109]. ATP and
UTP can induce tissue plasminogen activator release from
the vascular endothelium in vivo in man at submicromolar
concentrations [110]. On the other hand, uridine nucleotides
are highly potent stimulators of plasminogen activator
inhibitor-1 (PAI-1) expression and ATP or ADP suppress
PAI-1 expression in rat vascular smooth muscle cells [111]
suggesting a delicate balance in activation of the endoge-
nous fibrinolytic system by nucleotides.
The role of P2 receptors in the in the corneal wound
healing
Whereas our knowledge concerning the injury-induced
cellular responses elicited by extracellular nucleotides in
vitro is increasing at a rapid pace, very little is known about
their effect in vivo. The cornea is an excellent tissue to
study the response to injury because corneal epithelial cells
are superficial, avascular, and devoid of direct lymphatic
supply. P2Y1, P2Y2, P2Y4, P2Y6, and P2Y11 receptors
have been found in corneal epithelial cells and inhibition of
these receptors attenuated epithelial wound healing in vitro
[112]. Additionally, the presence of nucleotides in tears
may suggest a role in the healing process [113].
Studies of Pintor et al. have revealed that the application of
UTP increases the rate of healing in New Zealand white
rabbits whose corneas were injured with n-heptanol [114].
Weinger et al. have demonstrated that after injury of corneal
epithelial cells intracellular Ca
2+ wave propagating from the
site of injury to neighboring cells is mediated by the release
of extracellular nucleotides activating P2Y2 and P2Y4
receptors [115]. It has been suggested that the activation of
P2Y2 receptors accelerates the rate of corneal epithelial cell
migration while the stimulation of a P2Y6 does the opposite
[116]. Yin et al. have additionally demonstrated that the
release of endogenous ATP upon mechanical injury serves as
one of the extracellular mediators that trigger EGFR trans-
activation and the activation of its downstream signaling
pathways in corneal epithelial cells [11]. Recent in vivo
studies indicate that the P2X7 receptor also plays a
fundamental role in the corneal epithelium and stroma.
Through the use of P2X7 knockout mice, Mayo et al. have
shown that P2X7 is necessary for timely healing of abrasion
wounds and normal stromal collagen structure [117].
These findings and understanding pnenomena underly-
ing the response to injury in cornea may establish a
prototype for injury in other tissues. There are very few
reports of the use of extracellular nucleotides for the
enhancement of non-corneal wound healing. The efficacy
of UTP has been tested in an in vivo model of
dexamethasone-impaired wound healing in mice [10].
Topical treatment with a gel formulation of UTP improves
healing, which reaches the rate of normal, undisturbed
wounds. The in vivo studies on purinergic substances
confirm possibilities of development of new nucleotide
drugs in pharmacological wound care.
Conclusions
There is increasing interest in the therapeutic potential of
compounds that act through purinergic receptors for treating a
wide range of diseases. The P2Y2 receptor agonists diuridine
tetraphosphate (diquafosol) and the uracil cytosine dinucleo-
tide (denufosol) are currently undergoing clinical trials for dry
eye disease,retinal detachmentdisease,upper respiratorytract
symptoms, and cystic fibrosis [118]. Thienopyridine clopi-
dogrel is the most widely used blocker of ADP-induced
platelet aggregation [119]. It is clear that selective and stable
nucleotide compounds may also lead to applications P2
receptors’ agonists/antagonists in treating wound healing-
related diseases. Researches of the last decade have
demonstrated that also enzymes of nucleotide metabolism
could be novel targets for therapeutic intervention of wound
healing if we take into consideration the presence of
enzymes cleaving nucleotides. A detailed description of the
enzymatic reactions contributing to the pathways of extra-
cellular nucleotides’ degradation is beyond the scope of this
review but can be found in a number of recent reviews [e.g.,
202 Purinergic Signalling (2011) 7:193–206120]. After release into the extracellular space, ATP is
rapidly hydrolyzed by ecto-nucleotidases to pharmacologi-
cally active adenosine promoting wound healing itself
[reviewed in 105].
While much has recently been learned about the involve-
ment of extracellular nucleotides in wound healing, many
problems remain to be solved. We have to take into
consideration that nucleotide and adenosine receptors as well
as multiple ecto-nucleotidases are coexpressed in the same
cells and a mixture of extracellular nucleotides is released by
different kinds of cells. However, expanding our understand-
ing of a local purinergic signaling network in wound healing
maybe then translated to clinical benefit to use nucleotides or
their analogs for treatments of wound healing disorders.
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